Question explored with the scientific record
Conversation so far
- 1 Is there an effective treatment for ms?
- 2 Do these drugs help progressive MS, or only relapsing-remitting MS?
Answered on this page ↓
Do these drugs help progressive MS, or only relapsing-remitting MS?
The short version: the evidence you were given is almost entirely about relapsing-remitting MS, not progressive forms, so it does not answer your question.
The retrieved evidence contains no trial that directly tests a disease-modifying drug against placebo in progressive MS and measures disability progression as a primary endpoint. What exists is a handful of interferon-beta trials in secondary progressive MS (SPMS) that show a consistent pattern: they reduce relapses and MRI lesions, but the effect on disability progression is modest at best and inconsistent across studies [22]. The European trial of interferon beta-1b in SPMS showed a delay in EDSS progression, but the North American trial of the same drug was stopped early for futility on the primary endpoint [22]. Mitoxantrone, a chemotherapy agent, showed benefit in a composite outcome for worsening RRMS and SPMS combined, but carries known cardiotoxicity that limits cumulative dose [22]. Ocrelizumab is the only drug approved for primary progressive MS (PPMS), and the ORATORIO trial is not in this evidence set.
| MS Phase | What the evidence shows |
|---|---|
| Relapsing-remitting (RRMS) | Multiple trials show relapse reduction [2, 5, 8, 10] |
| Secondary progressive (SPMS) | Relapse reduction but inconsistent disability benefit [22] |
| Primary progressive (PPMS) | No trial in this evidence addresses it |
My call: for progressive MS, the evidence you have does not establish that any drug slows disability progression reliably. The trials that exist show a gap between reducing inflammatory relapses and stopping the neurodegenerative process that drives progressive disease. Confidence: low for any drug in progressive MS based on this evidence.
Sources examined 31
-
Treatment with interferon beta-1a in brazil is associated with fewer hospitalizations due to relapse, better adherence and a better response compared to other platform therapies
This study assesses compliance and discontinuation rates of disease-modifying therapies (DMTs) in Canadian patients with relapsing-remitting multiple sclerosis (RRMS), revealing that fingolimod has the highest compliance and lowest discontinuation rates compared to other DMTs.
DOI: 10.1016/j.jval.2016.03.234 -
Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: A Network Meta-Analysis
This study conducted a network meta-analysis of disease-modifying therapies for relapsing-remitting multiple sclerosis, finding that alemtuzumab, natalizumab, and ocrelizumab are the most effective treatments based on annualized relapse rates.
DOI: 10.1007/s40263-018-0541-5 -
Fingolimod: new oral treatment for relapsing‐remitting MS
This study evaluates the efficacy and safety of fingolimod as a disease-modifying therapy for adults with relapsing-remitting multiple sclerosis (RRMS), demonstrating significant reductions in relapse rates and disability progression compared to placebo and interferon beta-1a.
DOI: 10.1002/psb.859 -
Insights from Real-World Practice: The Dynamics of SARS-CoV-2 Infections and Vaccinations in a Large German Multiple Sclerosis Cohort
This study investigates the dynamics of SARS-CoV-2 infections and vaccinations in a large cohort of people with multiple sclerosis (pwMS) in Germany, revealing significant associations between demographic and disease-related factors and vaccination/infection rates.
DOI: 10.3390/vaccines12030265 -
Intravenous immunoglobulin treatment in multiple sclerosis Effect on relapses
A double-blind, placebo-controlled randomized trial in 40 relapsing-remitting MS patients shows that intravenous immunoglobulin (IVIg) treatment markedly reduces relapse rates and increases relapse-free time over 2 years, with favorable safety and some supportive MRI findings su…
DOI: 10.1212/WNL.50.2.398 -
Efficacy of High-Intensity Aerobic Exercise on Brain MRI Measures in Multiple Sclerosis
In this randomized phase 2 trial in people with multiple sclerosis, 24 weeks of supervised high‑intensity progressive aerobic exercise improved cardiorespiratory fitness and reduced relapse rate but did not reduce total brain atrophy (PBVC) compared with a waitlist control, with…
DOI: 10.1212/WNL.0000000000011241 -
Varicella-Zoster Virus Infections in Patients Treated With Fingolimod
This study assesses the incidence, risk factors, and clinical characteristics of varicella-zoster virus (VZV) infections in patients treated with fingolimod for multiple sclerosis, finding that while VZV infection rates are low, they are higher compared to placebo, and provides …
DOI: 10.1001/jamaneurol.2014.3065 -
Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study
A 96-week, randomized, double-blind, placebo-controlled phase III trial (CLARITY) evaluating the safety and tolerability of two intermittent cladribine tablet regimens in relapsing-remitting multiple sclerosis, showing increased lymphopenia and herpes zoster risk but overall acc…
DOI: 10.1177/1352458510391344 -
066 Impact of long-term teriflunomide treatment on lymphocyte counts and infections in pooled temso and tower studies
This study analyzes the long-term effects of teriflunomide treatment on lymphocyte counts and infections in patients with relapsing-remitting multiple sclerosis, revealing low rates of lymphopenia and similar infection rates in patients with and without lymphopenia.
DOI: 10.1136/jnnp-2018-anzan.65 -
Aggressive multiple sclerosis: proposed definition and treatment algorithm
This paper proposes a definition and treatment algorithm for aggressive multiple sclerosis (MS), emphasizing the need for early identification and intervention to prevent irreversible disability.
DOI: 10.1038/nrneurol.2015.85 -
Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study
In multiple sclerosis patients who were relapse-free for at least 5 years on injectable disease-modifying therapy, stopping treatment did not increase relapse risk compared with propensity-score matched stayers but significantly increased the hazard of disability progression, es…
DOI: 10.1136/jnnp-2016-313760 -
Rationale for early treatment with interferon beta-1a in relapsing-remitting multiple sclerosis
This article argues for and supports with trial data the initiation of interferon-beta-1a early in relapsing-remitting multiple sclerosis to slow disability progression and reduce MRI activity.
DOI: 10.1016/S0149-2918(97)80041-0 -
Multimodal predictors of disability progression and processing speed decline in relapsing–remitting multiple sclerosis
This study used a comprehensive multiverse analysis of a 12-year, multimodal Norwegian MS cohort to predict future disability progression (EDSS) and processing speed decline (PASAT), finding that disease-modifying treatment at long-term follow-up and certain baseline clinical/bi…
DOI: 10.1038/s41598-025-17894-2 -
Expansion of chronic lesions is linked to disease progression in relapsing–remitting multiple sclerosis patients
This longitudinal MRI study in relapsing-remitting multiple sclerosis (RRMS) shows that expansion of chronic white matter lesions is the primary driver of total lesion burden increase over 4 years, strongly associates with brain atrophy and disability progression, and is linked …
DOI: 10.1177/1352458520974357 -
Induction Therapy for Patients with Multiple Sclerosis: Why? When? How?
This study evaluates the efficacy and safety of induction therapy with mitoxantrone followed by maintenance therapy in patients with aggressive forms of multiple sclerosis, demonstrating significant reductions in disease activity and disability progression over a long-term follo…
DOI: 10.1007/s40263-013-0065-y -
The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study
A retrospective multicenter study in Italy analyzing the frequency and clinical correlates of immunosuppressant therapy in multiple sclerosis, finding ISA prescribed in about 32% of patients and associated with older therapy assignment, higher disability (EDSS), and a progressiv…
DOI: 10.1371/journal.pone.0157721 -
Neurofilaments in progressive multiple sclerosis: a systematic review
Neurofilament light chain (NFL) in CSF and blood consistently reflects inflammatory activity and future brain atrophy in progressive multiple sclerosis and responds to immunosuppressive disease-modifying therapies, while neurofilament heavy chain (NFH) findings are less consiste…
DOI: 10.1007/s00415-020-09917-x -
Intrathecally expanded GZMK+/GZMH+ CD8 T cells targeting EBV antigens may reduce severity of Multiple Sclerosis
A large, multi-omics CSF study in multiple sclerosis identifies intrathecal expansion of GZMK+/GZMH+ CD8+ T cells with EBV-specific TCRs that act as antiviral effectors, can kill autologous EBV-infected B cells, and whose activity correlates with lesion dynamics and may slow dis…
DOI: 10.1101/2025.08.05.25333071 -
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
The FREEDOMS II trial demonstrated that fingolimod significantly reduces annualized relapse rates and brain volume loss in patients with relapsing-remitting multiple sclerosis, although it did not show a significant effect on disability progression.
DOI: 10.1016/S1474-4422(14)70049-3 -
Assessing Treatment Effects on Axonal Loss - Evidence from MRI Monitored Clinical Trials
This study evaluates the effectiveness of various MRI techniques in monitoring axonal loss in multiple sclerosis (MS) patients and their correlation with clinical outcomes, highlighting the differential effects of disease-modifying therapies on inflammation and axonal damage.
DOI: 10.1177/197140090501800410 -
Is it possible to achieve cross-cultural european agreement in the assessment of neurological deficits? First experiences in the european interferon-beta 1B trial for secondary progressive MS
This study investigates the feasibility of achieving cross-cultural agreement in assessing neurological deficits through a training program in the European Interferon-Beta 1B trial for secondary progressive multiple sclerosis, demonstrating high inter-rater reliability among par…
DOI: 10.1016/0165-5728(95)98993-l -
Effect of drugs in secondary disease progression in patients with multiple sclerosis
A comprehensive review of major interferon-beta trials in secondary progressive multiple sclerosis (SPMS), showing consistent reductions in relapse rates and MRI activity but only modest or inconsistent effects on disability progression, with the European EUSPMS trial showing th…
DOI: 10.1191/1352458504ms1030oa -
Aggressive relapsing multiple sclerosis characterized by rapid disability progression
This study identifies criteria for aggressive relapsing multiple sclerosis (RMS) characterized by rapid disability progression, demonstrating that patients meeting these criteria are at high risk for severe long-term disability.
DOI: 10.1016/j.msard.2013.03.006 -
Rationale for early treatment with interferon beta-1a in relapsing-remitting multiple sclerosis
Early treatment with interferon beta-1a slows disability progression in relapsing-remitting multiple sclerosis, as supported by clinical trial data.
DOI: 10.1016/s0149-2918(97)80041-0 -
Interferon Beta and Long-term Disability in Multiple Sclerosis—Reply
A critical reply to claims about interferon beta use in relapsing-remitting multiple sclerosis, arguing that observed associations with disability progression in observational cohorts are heavily biased and that robust conclusions require prospective designs or advanced causal m…
DOI: 10.1001/jamaneurol.2013.1 -
Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy
This study investigates the production of neurotrophic factors in patients with relapsing-remitting and secondary progressive multiple sclerosis undergoing interferon beta therapy, revealing a significant increase in BDNF production in relapse-free RRMS patients after six months…
DOI: 10.1016/j.clim.2005.09.005 -
CD5-positive B cell subsets in secondary progressive multiple sclerosis
This study investigates the role of CD5-positive B cell subsets in secondary progressive multiple sclerosis (SPMS) and their association with disease severity and prognosis.
DOI: 10.1016/j.neulet.2012.06.041 -
Utility of the Rio Score and Modified Rio Score in Korean Patients with Multiple Sclerosis
This multicenter Korean retrospective study validates the Rio Score (RS) and Modified Rio Score (MRS), calculated after 6–15 months of interferon-beta therapy, as predictors of suboptimal relapse/EDSS progression over 3 years in Korean multiple sclerosis patients, supporting the…
DOI: 10.1371/journal.pone.0129243 -
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
This study compares the efficacy and safety of ocrelizumab, a humanized monoclonal antibody targeting CD20+ B cells, with interferon beta-1a in patients with relapsing multiple sclerosis, demonstrating that ocrelizumab significantly reduces relapse rates and disability progressi…
DOI: 10.1056/NEJMoa1601277 -
Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial
This study investigates the long-term effects of mitoxantrone induction therapy followed by interferon beta-1b in patients with aggressive relapsing multiple sclerosis, demonstrating significant delays in disability progression and reduced relapse rates compared to interferon tr…
DOI: 10.1136/jnnp.2010.229724 -
Immunomodulatory Agents for the Treatment of Relapsing Multiple Sclerosis
This 2002 systematic review synthesizes phase 3 randomized trials of immunomodulatory agents (interferon-beta 1b, interferon-beta 1a variants Avonex/Rebif, and glatiramer acetate) for relapsing MS, showing similar relapse reduction and MRI inflammatory effects across agents, wit…
DOI: 10.1001/archinte.162.19.2161